Sign up Australia
Proactive Investors - Run By Investors For Investors

WeedMD partners with world-renowned Technion-Israel Institute of Technology for cannabis research project

Technion is widely recognized as one of the global leaders in medical cannabis research
cannabis leaves
The project will research the profiles of 25 of WeedMD’s cannabis strains

Canadian marijuana producer and distributor WeedMD Inc (CVE:WMD) has joined the world-renowned Cannabis Database Project led by the Technion-Israel Institute of Technology.

Those in the project will be collaborating in the research of cannabinoid and terpenoid profiles of 25 of WeedMD’s cannabis strains.

READ: WeedMD now selling medical cannabis oil

This data will then be added to an international database that correlates the pharmacological effects of the different strains.

From there, the most effective cannabis treatments - strains, dose and route of administration - for clinical purposes can be determined.

This is the first of several research and development initiatives WeedMD is working on as the firm develops its medical cannabis for both the domestic and global markets.

“We are proud to be at the forefront of investing in cannabis research, awareness and education,” said chief scientific officer Luc Duchesne.

“There are hundreds of cannabis strains available to medical patients, but each of these strains has a unique chemical profile, as well potentially unique medical properties.

“A significant barrier to the standardization of medical cannabis is identifying strains that are effective in the treatment of specific medical conditions and Technion is making ground-breaking discoveries to this effect.”

WeedMD shares rose 3.7% to C$2.26 on Wednesday morning.

Join our Crypto, Blockchain and Cannabis Telegram group here
View full WMD profile View Profile

WeedMD Inc. Timeline

Related Articles

Woman holding cannabis leaf
October 16 2018
Canadian subsidiary Crystal Mountain is expanding its range of hydroponics equipment to meet expected demand.
Laboratory testing
October 10 2018
Fifteen patients have been enrolled in the trial being carried out at Children’s Hospital of Philadelphia in the USA.
cannabis leaf and green tablets
October 30 2018
The company will now proceed with stage II of the human clinical trial.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use